Eighteenth International Kidney Cancer Symposium, November 15-16, 2019, Trump National Doral Miami Hotel, Miami, Florida
CONTENTS
01 A phase 2 open label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: the BREAKPOINT trial S1
02 A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma S1
03 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) of intermediate or poor risk S2
04 Adrenal Metastases as Sanctuary Sites in Advanced RCC S3
05 Age-related trends in initial systemic therapy for metastatic clear cell renal cell carcinoma (mRCC) S3
06 Agnostic Transcriptional Profiling of The Cancer Genome Atlas Data Identifies Distinct and Cooperative Role of TP63 Isoforms in Renal Cancer Subtypes That Drive Progression and Predict Clinical Outcomes S4
07 An Exploratory Study of 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma S5
08 Association Between Depth of Response and Overall Survival: Exploratory Analysis in Patients With Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214 S5
09 Association of academic rank and productivity with metrics of Twitter utilization amongst kidney cancer experts S7
10 Association of clinical benefit (CB) from first-line (1L) treatment and CB in further lines or overall survival (OS) in metastatic renal cell carcinoma (mRCC) S7
11 Associations between inflammation, depression, and cancer stage in patients with resected renal cell carcinoma S8
12 Bilateral Multifocal Clear cell papillary renal cell carcinoma with discordant histopathology S9
13 Body composition and outcomes to Immune-Oncology agents in 165 patients with metastatic clear cell renal cell carcinoma S9
14 BONSAI trial: a prospective trial evaluating a first line treatment with cabozantinib in metastatic collecting duct carcinoma. S10
15 Brain Metastasis from Renal Cell Carcinoma: an Institutional Study S11
16 Choosing First-Line Treatment for Metastatic Renal Cell Carcinoma (mRCC) in the Immuno-oncology (IO) Era: Systematic Review and Network Meta-Analysis S11
17 Chromosome 8 Deficient Clear Cell RCC: An Analysis of Clinicopathologic Characteristics S12
18 Circulating Tumor DNA (ctDNA) results in 110 Patients with Advanced Renal Cell Carcinoma S13
19 Clinical correlates of oncogenic events in translocation renal cell carcinoma S14
20 Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC) S16
21 Combining immunotherapy and VEGFR inhibition improves the outcomes of elderly and favorable risk patients with metastatic renal cell carcinoma S16
22 Connections between BAP1 and the Type I Interferon Pathway in ccRCC S17
23 Cytoreductive Nephrectomy for Symptomatic Primary Tumors: Important Therapeutic Endpoint in the Management of mRCC S17
24 Development and validation of a risk score based on patient characteristics to predict major complications after partial nephrectomy S18
25 DNA hypomethylating agents activate ERV expression in kidney cancer to potentially enhance response to immunotherapies S19
26 Effects of immune checkpoint inhibitors on the morphology of renal cell carcinoma S20
27 Efficacy of Nivolumab (NIVO) plus Ipilimumab (IPI) in metastatic Renal Cell Carcinoma (RCC) and brain metastases. S21
28 Efficacy of Systemic Treatment After Cabozantinib Failure in Metastatic Renal Cell Carcinoma S22
29 Exploratory Analysis of Adherence to Anticancer Therapies in Metastatic Renal Cell Carcinoma in the United States (US) S23
30 Fine Needle Aspiration Based Immune Organoids Recapitulate TME in ccRCC Cancer S23
31 Genomic sequencing of high-grade unclassified renal cell carcinoma allows molecular stratification and improves prognostication S24
32 Identification of Oncocytic Neoplasms with Cyclin D1 Immunohistochemistry S25
33 Immunologic correlates of previously-treated metastatic renal cell carcinoma (mRCC) patients (pts) treated on a phase II trial of intermittent nivolumab therapy S26
34 Improved response rate of Cabozantinib after immune checkpoint therapy in patients with metastatic Renal Cell Carcinoma S26
35 Incidence of Occult Brain Metastases Detected at Study Screening in Patients with Advanced Renal Cell Carcinoma S27
36 Interim results of a phase 2 study of sapanisertib in patients with previously treated advanced renal cell carcinoma S28
37 Is anesthesia associated with oncological outcomes after nephrectomy S29
38 Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes S30
39 Long-Term Follow-Up of Nivolumab Versus Everolimus in Patients With Advanced Renal Cell Carcinoma (aRCC): The Phase 3 CheckMate 025 Trial S31
40 Loss of SETD2 drives mitochondrial dysfunction in clear cell renal cell carcinoma S32
41 Loss of tumor suppressor SETD2 alters identity of centromeric chromatin and promotes generation of neocentromeres S32
42 Mitotic defects and delays are characteristic features of SETD2 loss S33
43 Molecular chaperones Hsp70 and Hsp90 stabilize and maintain HIF2a activity in ccRCC S34
44 Multicenter Randomized Phase III Trial of Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors: a DaRenCa and NoRenCa Trial Evaluating
the Impact of Surgery or No Surgery. The NORDIC-SUN-Trial S34
45 Need for Sex Disaggregated Data in Outcomes Reporting for the Treatment of Renal Cell Carcinoma with Immunotherapy S35
46 Neutrophil-to-lymphocyte ratio in unclassified renal cell carcinoma is associated with outcome and differs between molecular subgroups S36
47 Nuances in surgical selection for cytoreductive nephrectomy among IMDC intermediate-poor risk patients S37
48 Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: North American Results from a global patient survey in 43 countries S38
49 PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704) S39
50 Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: Outcomes by IMDC Risk and Sarcomatoid Subgroups of the Phase 3 KEYNOTE-426 Study S40
51 Perspective Matters: Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes S41
52 PET-CT as predictor of response in the clear-cell metastatic renal cell carcinoma (mRCC) treatment S41
53 Phase 2 study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): results of an interim analysis S42
54 Phase II Trial of Intermittent Therapy in Patients (pts) with Metastatic Renal Cell Carcinoma (mRCC) Treated with Front-line Ipilimumab and Nivolumab (Ipi/Nivo) S43
55 Physician Rationale for Prescribing Tyrosine Kinase Inhibitors and Immuno-Oncology Treatments in the First-Line Treatment of Advanced Renal Cell Carcinoma in the United States: Interim Results from a Cross-Sectional Real-World Survey S44
56 Pilot study to evaluate the biologic effect of the probiotic CBM588 in combination with nivolumab/ipilimumab for patients with mRCC S45
57 Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma (RCC) S45
58 Prognostic Values of Pretreatment Lymphocite-to-Monocite Ratio in Patients with in Non-Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis S46
59 PROSPER: A phase III randomized study comparing perioperative nivolumab vs. observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143) S47
60 Protocol for a feasibility study of a cohort embedded randomised controlled trial comparing NEphron Sparing Treatment (NEST) for small renal masses S48
61 Quality of Life in Previously Untreated Patients With Advanced Renal Cell Carcinoma (aRCC) in Checkmate 214: Updated Results S49
62 Radiomic signatures of CD8+ T cell infiltration and PD-L1 expression in clear-cell renal cell carcinoma (ccRCC) S50
63 Real-World Clinical Outcomes Of Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving First-Line (1L) Therapy In The United States (US) Veteran Population S51
64 Real-world results from one year of therapy with tivozanib S51
65 Real-World Treatment Patterns Among Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Therapy in the United States Veteran Population S52
66 Renal cell carcinoma induced by end stage renal disease: A population-based study in Sweden S52
67 Resectable non-clear cell renal cell carcinoma: 25 years of single-center experience S53
68 Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: interim analysis of CheckMate 920 S54
69 Safety and Feasibility of Surgery Following Preoperative Immunotherapy in Patients with Metastatic Renal Cell Carcinoma S54
70 Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma S55
